Cleo Diagnostics Ltd (COV.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.295 (-3.28%) as of
Key statistics
- Market cap
- 42.00M
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.2700 – 0.9000
- Beta
- 0.52
- Revenue (TTM)
- 1.72M
- Profit margin
- 0.00%
- Volume
- 47.54k
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.